GFL Environmental Inc. Subordinate voting shares no par value vs Sana Biotechnology Inc — how do they compare? GFL Environmental Inc. Subordinate voting shares no par value trades at $42.64 (market cap $18.46B), while Sana Biotechnology Inc trades at $2.85 (market cap $836.71M). The key difference: GFL Environmental Inc. Subordinate voting shares no par value is far larger — about 22.1× Sana Biotechnology Inc's market cap, and GFL Environmental Inc. Subordinate voting shares no par value pays a 0.16% dividend while Sana Biotechnology Inc pays none. Which is the better fit depends on your goals.
| GFL | SANA | |
|---|---|---|
Market Cap | $18.46B | $836.71M |
Volume | 2,438,353 | 4,507,444 |
Sector | Industrials | Health |
52-Week High | $46.51 | $5.92 |
52-Week Low | $33.54 | $2.68 |
Typical Hold Time | 1 Days | — |
Enterprise Value | $25.43B | $749.96M |
Dividend Yield | 0.16% | — |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
SANA Biotechnology trades at $2.83, up 4.04% today, but faces significant fundamental challenges with negative revenue, substantial losses, and bearish technical indicators. The company reported a net loss of $244.17 million in 2025 with no revenue generation, while technical analysis shows a bearish trend with moving averages and ADX indicators signaling selling pressure. Recent investor conference presentations highlight ongoing business development activities.
Despite 82% analyst buy ratings and a $9.50 consensus price target, SANA carries high risk due to pre-revenue status, negative cash flow, and shareholder litigation concerns. The stock's investment case hinges on successful clinical development and future commercialization of its engineered cell therapies, requiring careful risk assessment by investors.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
GFL Environmental provides environmental services across Canada and the United States. Its operations include solid waste management and other waste and environmental solutions.
Read more on GFL →Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →